Humacyte, Inc. Basic Shares Outstanding (Weighted Average)
Humacyte, Inc. (HUMA) reported Basic Shares Outstanding (Weighted Average) of 234.18 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-12
- Humacyte, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 234.18M shares, a 50.66% increase year-over-year.
- Humacyte, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 197.85M shares, a 50.46% increase year-over-year.
- Humacyte, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 187.10M shares, a 47.27% increase year-over-year.
- Humacyte, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 158.31M shares, a 32.58% increase year-over-year.
- Humacyte, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 158.16M shares, a 33.49% increase from fiscal 2024.
- Humacyte, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 118.48M shares, a 14.56% increase from fiscal 2023.
- Humacyte, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 103.42M shares, a 0.36% increase from fiscal 2022.
- Humacyte, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 103.05M shares, a 157.82% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 234.18M shares 10-Q · filed 2026-08-12 | 216.11M shares 10-Q · filed 2026-08-12 | 206.38M shares derived: average of 3 quarters · filed 2026-08-12 | 194.36M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 197.85M shares 10-Q · filed 2026-05-13 | 192.47M shares derived: average of 2 quarters · filed 2026-05-13 | 181.09M shares derived: average of 3 quarters · filed 2026-05-13 | 174.67M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | 187.10M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | 172.71M shares derived: average of 2 quarters · filed 2026-03-27 | 166.95M shares derived: average of 3 quarters · filed 2026-08-12 | 158.16M shares 10-K · filed 2026-03-27 |
| 2025-09-30 | 158.31M shares 10-Q · filed 2025-11-12 | 156.88M shares derived: average of 2 quarters · filed 2026-08-12 | 148.51M shares 10-Q · filed 2025-11-12 | 143.07M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | 155.44M shares 10-Q · filed 2026-08-12 | 143.53M shares 10-Q · filed 2026-08-12 | 137.99M shares derived: average of 3 quarters · filed 2026-08-12 | 133.35M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | 131.50M shares 10-Q · filed 2026-05-13 | 129.27M shares derived: average of 2 quarters · filed 2026-05-13 | 125.98M shares derived: average of 3 quarters · filed 2026-05-13 | 124.28M shares derived: average of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | 127.05M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | 123.23M shares derived: average of 2 quarters · filed 2026-03-27 | 121.88M shares derived: average of 3 quarters · filed 2026-03-27 | 118.48M shares 10-K · filed 2026-03-27 |
| 2024-09-30 | 119.41M shares 10-Q · filed 2025-11-12 | 119.29M shares derived: average of 2 quarters · filed 2025-11-12 | 115.62M shares 10-Q · filed 2025-11-12 | 112.61M shares derived: average of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | 119.17M shares 10-Q · filed 2025-08-11 | 113.71M shares 10-Q · filed 2025-08-11 | 110.34M shares derived: average of 3 quarters · filed 2025-08-11 | 108.62M shares derived: average of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | 108.25M shares 10-Q · filed 2025-05-13 | 105.93M shares derived: average of 2 quarters · filed 2025-05-13 | 105.10M shares derived: average of 3 quarters · filed 2025-05-13 | 104.67M shares derived: average of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | 103.61M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 103.53M shares derived: average of 2 quarters · filed 2025-03-31 | 103.47M shares derived: average of 3 quarters · filed 2025-03-31 | 103.42M shares 10-K · filed 2025-03-31 |
| 2023-09-30 | 103.44M shares 10-Q · filed 2024-11-08 | 103.40M shares derived: average of 2 quarters · filed 2024-11-08 | 103.36M shares 10-Q · filed 2024-11-08 | 103.31M shares derived: average of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | 103.36M shares 10-Q · filed 2024-08-13 | 103.31M shares 10-Q · filed 2024-08-13 | 103.26M shares derived: average of 3 quarters · filed 2024-08-13 | 103.21M shares derived: average of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | 103.26M shares 10-Q · filed 2024-05-13 | 103.21M shares derived: average of 2 quarters · filed 2024-05-13 | 103.15M shares derived: average of 3 quarters · filed 2024-05-13 | 103.12M shares derived: average of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | 103.16M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 103.10M shares derived: average of 2 quarters · filed 2024-03-28 | 103.07M shares derived: average of 3 quarters · filed 2024-03-28 | 103.05M shares 10-K · filed 2024-03-28 |
| 2022-09-30 | 103.03M shares 10-Q · filed 2023-11-09 | 103.02M shares derived: average of 2 quarters · filed 2023-11-09 | 103.01M shares 10-Q · filed 2023-11-09 | 103.18M shares derived: average of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | 103.01M shares 10-Q · filed 2023-08-14 | 103.00M shares 10-Q · filed 2023-08-14 | 103.24M shares derived: average of 3 quarters · filed 2023-08-14 | 88.41M shares derived: average of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | 103.00M shares 10-Q · filed 2023-05-12 | 103.35M shares derived: average of 2 quarters · filed 2023-05-12 | 83.55M shares derived: average of 3 quarters · filed 2023-05-12 | 64.15M shares derived: average of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | 103.70M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | 73.82M shares derived: average of 2 quarters · filed 2023-03-24 | 51.20M shares derived: average of 3 quarters · filed 2023-03-24 | 39.97M shares 10-K · filed 2023-03-24 |
| 2021-09-30 | 43.95M shares 10-Q · filed 2022-11-10 | 24.95M shares derived: average of 2 quarters · filed 2022-11-10 | 18.73M shares 10-Q · filed 2022-11-10 | 15.39M shares derived: average of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | 5.94M shares 10-Q · filed 2022-08-12 | 5.91M shares 10-Q · filed 2022-08-12 | 5.87M shares derived: average of 3 quarters · filed 2022-08-12 | 5.85M shares derived: average of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | 5.87M shares 10-Q · filed 2022-05-13 | 5.84M shares derived: average of 2 quarters · filed 2022-05-13 | 5.82M shares derived: average of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | 5.80M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 5.79M shares derived: average of 2 quarters · filed 2022-03-29 | 5.77M shares 10-K · filed 2022-03-29 | |
| 2020-09-30 | 5.79M shares 10-Q · filed 2021-11-15 | 5.76M shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |